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Virus entry into cells is typically initiated by binding of
virally encoded envelope proteins to specific cell
surface receptors. Studying infectivity of lentivirus
pseudotypes lacking envelope binding, we still
observed high infectivity for some cell types. On
further investigation, we discovered that this infec-
tivity is conferred by the soluble bovine protein S in
fetal calf serum, or Gas6, its human homolog. Gas6
enhances native infectivity of pseudotypes of
multiple viral envelope proteins. Gas6 mediates
binding of the virus to target cells by bridging virion
envelope phosphatidylserine to Axl, a TAM receptor
tyrosine kinase on target cells. Phagocytic clearance
of apoptotic cells is known to involve bridging by
Gas6. Replication of vaccinia virus, which was previ-
ously reported to use apoptotic mimicry to enter
cells, is also enhanced by Gas6. These results reveal
an alternative molecular mechanism of viral entry
that can broaden host range and enhance infectivity
of enveloped viruses.
INTRODUCTION
Binding of virus to target cells, the first step of viral infection, is
usually mediated by viral proteins that can bind directly to recep-
tors expressed on target cells (Norkin, 2010). The affinity and
specificity of receptor-binding viral proteins can determine the
efficiency of replication in target cells and the tropism of the
virus. Abundant expression of high-affinity receptor-binding
molecules on the surface of viruses is an ideal condition for viral
replication.
Viruses use several strategies to facilitate efficient binding to
target cells. One means is a single viral protein binding to
multiple receptors. For example, the HIV envelope protein,
gp120, binds to its primary receptor CD4 (Dalgleish et al.,
1984) but also C types lectins, including DC-SIGN (Geijtenbeek
et al., 2000), to facilitate gp120-CD4 interaction, resulting in286 Cell Host & Microbe 9, 286–298, April 21, 2011 ª2011 Elsevier Inincreased HIV replication in target cells expressing both CD4
and DC-SIGN (Lee et al., 2001). Another approach is through
use of multiple viral proteins for binding. For example, the intra-
cellular mature virus (IMV) form of vaccinia virus contains at least
three viral envelope proteins that bind to the viral receptor,
glycosaminoglycans (Smith et al., 2002).
However, viruses can mediate efficient binding to target cells,
despite low affinity and density of receptor-binding viral
proteins. One means is by utilizing soluble proteins present in
bodily fluids to bridge the virus to target cells. For example,
amyloid fibrils in semen can enhance HIV replication more
than 10-fold by bridging virus to target cells in an envelope
protein-independent manner (Munch et al., 2007). Infection of
one type of nonenvelope virus, adenovirus, can also be
enhanced by soluble factors in serum (Shayakhmetov et al.,
2005; Waddington et al., 2008). Enhancement of adenoviral
transduction by soluble factors was observed during develop-
ment of targeting vectors that can specifically transduce
selected cell types. Binding of adenovirus is mediated by viral
penton proteins. Previous attempts to redirect adenovirus
vectors via ablation of receptor-binding regions of penton
proteins were unable to eliminate their liver tropism. It was
recently found that binding of adenovirus vectors to the liver is
mediated by factors IX and X, which are serum proteins in the
coagulation system, bridging adenovirus to target cells. We
developed targeting retroviral vectors, including both g-retro-
viral and lentiviral vector types. Binding of a retrovirus is usually
mediated by its envelope proteins, but modification of receptor-
binding regions of retroviral envelope proteins often results in
loss of fusion activity (Zhao et al., 1999). Unlike retroviral enve-
lope proteins, the receptor-binding regions of the Sindbis virus
envelope proteins can be modified without losing fusion activity
(Ohno et al., 1997). We pseudotyped retroviral vectors with
modified Sindbis virus envelope proteins and successfully redir-
ected their tropisms in vitro and in vivo (Morizono et al., 2001,
2005). Although we eliminated the original tropism of the Sindbis
virus envelope protein by mutating its known receptor-binding
regions, we still observed significant residual infectivity for
certain cell types. Because complete elimination of nontargeted
transduction is necessary to minimize adverse effects of
lentiviral transduction, we attempted to eliminate the residualc.
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nism of this residual infectivity, we found that a soluble protein,
Gas6, enhances binding of envelope viruses by binding to one
type of lipid, phosphatidylserine (PtdSer), on virions and the
TAM receptors on the cell surface.
RESULTS
Fetal Calf Serum Increases Transduction Efficiencies
of Lentiviral Vectors Pseudotyped with Various Types
of Envelope Proteins
For several years, we have developed pseudotyped lentiviral
vectors that can specifically transduce certain target cells
due to modification of Sindbis virus envelope pseudotypes,
whereby the original receptor-binding regions were ablated.
New target tropisms were then conferred to the envelope
protein by conjugation with targeting ligands directed to cell
surface molecules. During vector development, we noticed
that despite ablation of native receptor-binding activity, residual
infectivity persisted, typically less than 3%, but as high as 50%–
70% of wild-type activity in some experimental settings. These
observations suggested an unknown interaction between the
virus and target cells that contributed to binding and infectivity.
We investigated this infectivity further by identifying its source,
characterizing its properties, and ultimately determining its
molecular identity.
In our initial experimental system, we utilized humanmicrovas-
cular endothelial cells (HMVECs) (Shao and Guo, 2004), since
they demonstrate a high level of infectivity even when the native
receptor-binding activity is ablated. The titer of the lenvitial
vector (containing 1000 ng HIV p24/ml) pseudotyped with the
vesicular stomatitis G protein (VSV-G), which is commonly
used due to its high transduction efficiency, is typically 1 3 106
EGFP transduction unit (TU)/ml on HMVEC in the presence of
10% fetal calf serum (FCS). Under the same conditions, the titer
of the vector pseudotyped with the wild-type Sindbis virus
envelope protein is 4 3 105 EGFP TU/ml, while the titer of
lentiviral vectors pseudotyped with mutant Sindbis virus enve-
lope proteins, which should have minimal receptor binding, is
as high as 2 3 105 EGFP TU/ml. We first determined that the
origin of the factor(s) responsible for the residual infectivity was
present in FCS. HMVEC were minimally transduced with the
vector (2.2 1L1L pseudotype) when cells are preincubated with
PBS containing CaCl2, MgCl2, and BSA (PBS [+]) (Figures 1A
and 1B). However, we found that transduction drastically
increased when the cells were preincubated with higher concen-
trations of FCS (Figure 1B). This enhanced transduction was
blocked by a reverse transcriptase inhibitor (Nevirapine), demon-
strating that EGFP expression is not caused by pseudotransduc-
tion mediated via contaminated EGFP proteins in the virus.
Transduction by VSV-G pseudotype was not significantly
enhanced (Figure 1B), suggesting that enhancement occurred
during entry of 2.2 1L1L pseudotype. This enhancement of the
2.2 1L1L pseudotype is concentration dependent and saturated
at 10% FCS (Figure 1C). Enhancement was observed regardless
of transducing virus amount, although the extent of enhance-
ment was more obvious with lower virus amounts (Figure 1D).
Enhanced viral transduction was observed with five different
FCS lots.CellAn FCS Factor(s) Enhances Transduction of Vectors
Pseudotyped with Multiple Types of Envelope Proteins
We initially assumed that enhancement of transduction by FCS is
specific to viruses containing the envelope proteins derived from
Sindbis virus. To test this, we determined the effect on lentiviral
vectors pseudotyped with other viral envelope proteins including
wild-type Sindbis virus; Ross River virus, which belongs to the
same alphaviridae as Sindbis virus; and baculovirus, which
belongs to baculoviridae. Surprisingly, the vectors pseudotyped
with the envelope proteins of these viruses were also enhanced
(Figure 2A). Thus, the enhancement is not specific to particular
types of envelope proteins. Of note, transduction with virus lack-
ing viral envelope protein did not occur, regardless of incubation
with FCS (Figure 2A), indicating that the presence of viral enve-
lope proteins is required for enhancement.
Enhancement of Viral Transduction by a Factor(s)
in FCS Requires Divalent Cations
Since it appeared that there was a factor(s) in FCS that can
enhance transduction, we elucidated the properties of this factor
in preparation for subsequent purification. Initially we investi-
gated whether this enhancement requires Ca2+ and/or Mg2+,
which are important for the functions of many proteins. To do
so, we used themodified Sindbis virus envelope protein contain-
ing the Fc-binding region of protein A (ZZ), designated 2.2
(Figure 1A). We found that FCS-mediated enhancement of trans-
duction with the 2.2 pseudotype is inhibited by EGTA. We previ-
ously demonstrated that the tropism of 2.2 pseudotypes can be
redirected by conjugation of the ZZ domain with antibodies
recognizing chosen cell surface molecules (Pariente et al.,
2007). One receptor, HLA class I expressed ubiquitously on
human cells, is efficiently recognized by an anti-HLA class I anti-
body (aHLA Ab) and allows binding and transduction of cells
(Morizono et al., 2001). A control transduction mediated by
HLA class I on the cell surface was not inhibited by EGTA (Fig-
ure 2B). These results demonstrated that binding of the factor
to cells and/or virus is Ca2+ and/or Mg2+ dependent.
We determined the step of infection enhanced by the FCS
factor(s) by first examining the effect of the factor(s) on viral
binding to cells. To quantitate binding of virus, we labeled the
2.2 1L1L pseudotype with EGFP and assessed binding of the
labeled virus to cells (Figure 2C). Binding of virus was signifi-
cantly enhanced when HMVECs were incubated with FCS.
FCS-mediated enhancement of viral binding was inhibited by
EGTA. These results demonstrated that FCS increases binding
of virus to cells in a Ca2+- and/or Mg2+-dependent manner.
An FCS Factor(s) Enhances Viral Transduction
by Bridging Virus to Cells
There are two possible mechanisms of enhancement of viral
binding by FCS: (1) a factor(s) in FCS upregulates novel binding
receptors for virus on the cells, and (2) FCS contains a factor(s)
that can bridge the virus to cells. To investigate the first hypoth-
esis, before transduction with the 2.2 1L1L pseudotype, we incu-
bated the cells with FCS, either using cycloheximide, or at 4C
instead of 37C to block de novo synthesis of proteins, but
neither decreased enhancement by FCS (data not shown), sug-
gesting that upregulation of a receptor is unlikely to be themech-
anism for enhanced transduction.Host & Microbe 9, 286–298, April 21, 2011 ª2011 Elsevier Inc. 287
Figure 1. FCS Enhances Transduction with Lentiviral Vectors Pseudotyped with Various Types of Envelope Proteins
(A) Schematic representation of chimeric Sindbis virus envelope proteins. The Sindbis virus envelope protein is first synthesized as a polypeptide and subse-
quently cleaved by cellular proteases to generate the E3, E2, 6K, and E1 proteins. E1 and E2 are incorporated into the viral envelope. Both 2.2 and 2.2 1L1L were
derived from thewild-type Sindbis virus envelope protein withmutations (shown as red lines) to reduce their binding to original receptors. In addition, 2.2 1L1L has
two flexible linkers and 2.2 contains the ZZ domain at the E2 amino acid 70.
(B) For all transduction and infection experiments, 1 3 104 HMVECs per well were seeded into 48-well plates 2 days before infection or transduction. Total
infection/transduction volume was 150 ml. HMVECs were incubated with PBS (+) or 10% FCS in PBS (+), followed by transduction with 2.2 1L1L (100 ng p24/ml).
Nevirapine (5 mM) was used 30 minutes before, during, and after transduction. VSV-G-pseudotype (10 ng p24/ml) was also used instead of the 2.2 1L1L
pseudotype.
(C) HMVECs were incubated with different concentrations of FCS in PBS (+) and transduced with the 2.2 1L1L pseudotype (100 ng p24/ml).
(D) The enhancing effects of 10% FCS on HMVEC transduction were investigated, using various concentrations of 2.2 1L1L pseudotype. (C and D) The error bars
represent standard deviations of triplicated experiments.
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bridges the virus to cells, we first incubated virus with FCS,
then purified the virus by ultracentrifugation and transduced
HMVEC with these treated viruses (see Figure S1A available
online). The virus incubated with FCS showed increased trans-
duction efficiency. When virus was incubated with FCS in the
presence of EGTA, enhancement of transduction was inhibited.
These results indicate that FCS enhances viral transduction,
most likely through a factor(s) that bridges the virus to HMVEC
in a Ca2+- and/or Mg2+-dependent manner.
In Figure 2A, we showed that transduction with the viruses
pseudotyped with various envelope proteins was enhanced by
FCS, but not by virus lacking viral envelope proteins; therefore,
we hypothesized that the factor(s) may bind to viruses indepen-
dent of viral envelope proteins but still requires viral envelope
proteins for subsequent fusion steps. To determine whether
the factor(s) binds to virus independently of viral envelope
proteins, we used virus lacking viral envelope proteins (vEnv[])
to compete against the 2.2 1L1L pseudotype for binding by the
bridging factor(s) on HMVEC (Figure S1B). In the presence of288 Cell Host & Microbe 9, 286–298, April 21, 2011 ª2011 Elsevier InvEnv(), enhancement of 2.2 1L1L pseudotype transduction by
FCSwas inhibited. As a control, transduction of HMVEC (without
preincubation with FCS) with the 2.2 pseudotype conjugated
with aHLA Ab was not affected by vEnv(). These results
suggest that the bridging factor(s) binds to the virus independent
of viral envelope proteins, but dependent on an unknown virion-
associated factor(s).
Bovine Protein S Mediates Bridging of Virus to Cells
To elucidate the mechanism by which virus bridges to cells, we
attempted to isolate the bridging factor from FCS. The
enhancing activity of FCS is inactivated by treating FCS with
DTT or incubation at 80C (data not shown), suggesting that
the factor is a protein. We used consecutive fractionation
methods to purify the factor (Figure 3A).We first used ammonium
sulfate precipitation to fractionate FCS, which most efficiently
concentrated the factor at a saturation concentration of 33%–
38% (data not shown). We used this fraction to further purify
the factor, using a combination of different types of FPLC in
the following order: hydroxylappatite, anion exchange, andc.
Figure 2. FCSBridges Virus toCells in an Envelope Protein-Indepen-
dent Manner
(A) HMVECs were incubated with PBS (+) or 10% FCS in PBS (+) then trans-
duced with various pseudotypes. vEnv() was also used for transduction. The
concentrations of viruses used for transduction are shown in the figure. N.D.,
not detected.
(B) (Left) HMVECs were incubated with 10% FCS in PBS (+) or PBS (EGTA)
followed by transduction with the 2.2 pseudotype (100 ng p24/ml) in PBS (+) or
PBS (EGTA). (Right) HMVECs were transduced with the 2.2 pseudotype
(100 ng p24/ml) conjugated with aHLA Ab (2 mg/ml) in PBS (+) or PBS (EGTA).
(C) HMVECs were incubated with PBS (+), 10% FCS in PBS (+), or 10% FCS in
PBS (EGTA) for 4 hr. The cells were incubated with the 2.2 1L1L pseudotype
labeled by EGFP (100 ng p24/ml) for 2 hr. (A–C) The error bars and values after ±
represent standard deviations of triplicated experiments. (See also Figure S1.)
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Cellsize exclusion. We assessed the ability of purified fractions to
enhance viral transduction as well as the protein concentrations
of purified fractions to those of FCS and checked whether the
bridging factor was concentrated after each fractionation (Fig-
ure 3A). We analyzed the proteins in the final size-exclusion frac-
tion showing the highest activity by SDS-PAGE and SyproRuby
staining (Figure 3B). We found five bands in this fraction and
identified each band by mass spectrometry. The five bands
were identified as fibronectin, C3, CFH, C4, and protein
S. Because purified proteins of the human homologs are more
readily obtained than bovine proteins, we tested the effects of
these proteins on HMVEC transduction with the 2.2 1L1L pseu-
dotype using human homologs. We tested both human Gas6
(hGas6) and protein S (hProtein S) because both are functional
homologs of bovine protein S (bProtein S) (Hafizi and Dahlback,
2006). Human protein S and Gas6 increased the titers of the 2.2
1L1L pseudotype, although the effect of hGas6 was much
greater than that of hProtein S (Figure 3C). We also confirmed
that recombinant bProtein S increased transduction (Figure 3D).
Because antibodies that neutralize the function of bProtein S are
not available, we used soluble human Axl protein (sAxl),
a receptor for protein S and Gas6 lacking transmembrane
domain, which can bind bProtein S and potentially neutralize
its function, to confirm that the enhancement of virus transduc-
tion in FCS is mediated by bProtein S (Figure 3E) (Hafizi and
Dahlback, 2006). When FCS was incubated with sAxl before
addition to HMVEC, enhancement of viral transduction was
completely inhibited, while incubation with soluble human CD4
(sCD4) as a control had no effect. We also tested human factor
X, which was previously shown to increase transduction of
adenovirus (Parker et al., 2006), and found no effect (Figure 3C).
These results demonstrated that bProtein S in FCS and its
human homologs bridge the virus to cells.
Human Gas6 Efficiently Mediates Bridging of Virus
to Cells
We next tested the dose dependency of enhancement by human
protein S and Gas6 for enhancement of 2.2 1L1L transduction
(Figure 4A). Although both hGas6 and hProtein S increased
transduction, hGas6 enhanced transduction at concentrations
1,000- to 10,000-fold lower than hProtein S.
The N terminus region of protein S and Gas6, designated the
Gla domain, contains 7 or 8 Ca2+ and can bind to PtdSer (Hafizi
and Dahlback, 2006). Binding to PtdSer requires Ca2+ and
g-carboxylation of the Gla domain by vitamin K-dependentHost & Microbe 9, 286–298, April 21, 2011 ª2011 Elsevier Inc. 289
Figure 3. The Bridging Factor in FCS Is
bProtein S
(A) FCS was fractionated by precipitation with
various concentrations of ammonium sulfate (5%
increments). The proteins precipitated with 33%–
38% ammonium sulfate had the highest
enhancing activity/mg of protein andwere used for
subsequent purification by FPLC using hydrox-
yappatite, anion-exchange, and size exclusion
columns. Each fraction was tested for enhance-
ment of transduction of HMVEC with the 2.2 1L1L
pseudotype. The fraction(s) showing the highest
enhancing activity was used for subsequent puri-
fication. The fold concentration of the purified
fractions was calculated by the following formula:
protein concentration of FCS necessary for
10-fold enhancement of HMVEC transduction with
2.2 1L1L pseudotype divided by protein concen-
tration of each fraction necessary for the same
enhancing activity. Because the protein concen-
tration of the fraction purified by size-exclusion
chromatography was too small to measure, fold
concentration could not be determined and is
shown as N.D.
(B) The size-exclusion chromatography fraction
which had the highest enhancing activity was
subjected to SDS-PAGE and SyproRuby staining.
The protein bands were then subjected to protein
identification bymass spectrometry. Since the two
bands migrated around 97 kD, we identified the
proteins in these two bands together.
(C) HMVECs were incubated with the human
homologues of the proteins identified in the puri-
fied fraction, followed by transduction with the 2.2
1L1L pseudotype (100 ng p24/ml).
(D) HMVECs were incubated with the supernatant
of 293T cells transfected with an expression
vector for bProtein S or control plasmid (pcDNA3)
or serum-free medium, followed by transduction
with the 2.2 1L1L pseudotype (100 ng p24/ml).
(E) Ten percent FCS was incubated with sAxl or
sCD4 (25 mg/ml) in PBS (+) for 1 hr and used to
incubate HMVEC for 4 hr. The cells were then
infected with the 2.2 1L1L pseudotype (100 ng
p24/ml). (C–E) The error bars represent standard
deviations of triplicated experiments.
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ing g-carboxylation (hGas6[g]) did not have any enhancing
effects (Figure 4A) (Nakano et al., 1997). We also found that
commercially available hGas6, which retains signaling activity
via TAM receptors but lacks g-carboxylation, could not enhance
viral transduction (data not shown). These results demonstrated
that g-carboxylation is necessary for enhancement of viral trans-
duction and suggested that one of the binding partners for
hGas6 may be PtdSer.
Since our experiments with the FCS factor indicated that the
factor increases binding of virus, we also investigated whether
hGas6 does so (Figure 4B). hGas6 enhanced binding of the 2.2
1L1L pseudotype in a Ca2+-dependent manner. hGas6(g) did
not have any enhancing effects, demonstrating that g-carboxyl-
ation is necessary for bridging of virus to cells and suggesting
that PtdSer on either cells or virions is involved in the binding.290 Cell Host & Microbe 9, 286–298, April 21, 2011 ª2011 Elsevier InWe further demonstrated entry of virus in the presence of
hGas6 using cytoplasmic CCF2 dye and virion-incorporated
b-lactamase (Cavrois et al., 2002) (Figure S2A). hGas6 enhanced
the binding of EGFP-labeled vEnv() (data not shown); however,
hGas6 did not mediate the entry of vEnv(). These results
confirmed that hGas6 can mediate binding of virus in an enve-
lope protein-independent manner, but envelope protein is
necessary for the subsequent fusion step.
hGas6 Increases Transduction of Various Pseudotypes
to Differing Extents
hGas6 also increased transduction of other viral pseudotypes,
similar to that observed with FCS (Figure 4C; compare with Fig-
ure 2A).Whenwecompared the extent of enhancement of various
pseduotypes to their infectivity (EGFP TU per the same amount of
virus [1 ng of p24 capsid protein]), we observed that the higher thec.
Figure 4. hGas6 Enhances Binding and Transduction of Lentiviral Vectors at Low Concentrations
(A) HMVECs were incubated with hProtein S, hGas6, or hGas6(g) at various concentrations (shown by ng/ml and M), followed by transduction with the 2.2 1L1L
pseudotype (100 ng p24/ml).
(B) HMVECs (13 105) were incubated with 100 ng/ml of hGas6 or hGas6(g) in PBS (+), or hGas6 in PBS (EGTA), then incubated with the 2.2 1L1L pseudotype
labeled by EGFP (250 ml, 100 ng p24/ml).
(C) HMVECs were incubated with PBS (+) or PBS (+) containing hGas6 (100 ng/ml), followed by transduction with various pseudotypes. vEnv() was also used for
transduction. N.D., not detected.
(D) HMVECswere incubatedwith PBS (+) or hGas6 (100 ng/ml) in PBS (+), followed by transductionwith the 2.2 pseudotypewith or without conjugationwith aHLA
Ab (2 mg/ml). (A–D) The error bars and values after ± represent standard deviations of triplicated experiments. (See also Figure S2.)
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ably because stronger binding between the virus and natural
receptors with high affinity and/or avidity masks the effects of
hGas6. To explore further this observation, we used the 2.2 pesu-
dotype where its infectivity can be increased by conjugation with
antibodies recognizing target cells, enabling us to investigate the
relationship between viral infectivity and the extent of hGas6-
mediated enhancement using the same virus pseudotype. Trans-
duction ofHMVECwith the 2.2 pseudotypewasenhanced33-fold
by preincubation of HMVEC with hGas6 (Figure 4D). Conjugation
of 2.2-pseudotyped vectors with aHLA Ab increased viral titersCellby 43-fold, while the extent of transduction enhancement by
hGas6 decreased both at high (1.6-fold) and low mois (2.4-fold)
(Figure 4D). Thus, the effect of hGas6 on viral transduction is
present among different pseudotypes but is most obvious when
binding of virus is not efficient due to low affinity and/or avidity
interaction between viral envelope proteins and its receptors. Of
note, the titer (EGFP TU/1 ml of virus containing 100 mg p24) of
2.2 1L1L with 130 pM hGas6 is 3.3 3 107 (Figure 4A), while the
wild-type Sindbis pseudotype without hGas6 is 1.8 3 107 (Fig-
ure 4C). Therefore, the entry pathway mediated by hGas6 is
efficient similar to infection via native receptor binding.Host & Microbe 9, 286–298, April 21, 2011 ª2011 Elsevier Inc. 291
Figure 5. hGas6 Binds to Axl on Target Cells
(A) Schematic representation of the mechanism whereby hGas6 mediates phagocytosis of dead cells.
(B) Expression of Axl, TYRO3, Mer, and PtdSer on HMVEC.
(C) HMVECs were incubated for 1 hr with PBS (+) or PBS (+) containing one blocking reagent (control IgG, anti-human Axl antibody, anti-human Mer antibody, or
ANX5) (25 mg/ml) and then incubated with hGas6 (100 ng/ml) in the presence of each blocking reagent for 4 hr. After removing hGas6 and blocking reagents, the
cells were transduced with the 2.2 1L1L pseudotype (100 ng p24/ml).
(D) Enhancement of viral transduction of 293T, Axl-293T, TYRO3-293T, andMer-293T cells mediated by hGas6 or hProtein S. Cells (13 105) were incubated with
PBS (+), PBS (+) containing hProtein S, or hGas6 (100 ng /ml), followed by transduction with the 2.2 1L1L pseudotype (100 ng p24/ml). The fold enhancement was
calculated by the following formula: percent of EGFP-expressing cells preincubated with hProtein S or hGas6 divided by percent of EGFP-expressing cells
preincubated with PBS (+).
(E) Expression of Axl, TYRO3, and Mer on 293T, Axl-293T, TYRO3-293T, and Mer-293T cells. Black and red lines are staining with isotype control antibodies and
antibodies against each type of TAM receptor, respectively. (C and D) The error bars represent standard deviations of triplicated experiments.
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for hGas6-Mediated Viral Transduction
Gas6 and protein S have two ligand-binding regions (Figure 5A)
(Hafizi and Dahlback, 2006). The N-terminal Gla domain binds to
PtdSer. The C-terminal region has a sex hormone-binding glob-
ulin (SHBG)-like structure that contains one Ca2+ and binds to292 Cell Host & Microbe 9, 286–298, April 21, 2011 ª2011 Elsevier InTAM receptors, including Axl,Mer, andTYRO3 (LemkeandRoth-
lin, 2008). One function of Gas6 and protein S is to bridge
apoptotic cells to phagocytes (Figure 5A). Gas6 and protein S
bind to PtdSer on apoptotic cells through the Gla domain and
TAM receptors on phagocytes using the SHBG-like domains.
This binding activates phagocytosis of dead cells by phagocytes.c.
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HMVEC (Figure 5B). HMVEC expressed Axl and PtdSer at signif-
icant levels, but only small amounts of Mer and no TYRO3. We
then used either anti-Axl or anti-Mer antibody to determine
whether these receptors are involved in hGas6-mediated trans-
duction (Figure 5C). The anti-Axl antibody completely blocked
hGas6-mediated transduction of HMVEC, while control IgG and
anti-Mer antibody did not have an effect. We also used annexin
V (ANX5), which binds to PtdSer, to block binding of hGas6 to
the cells. Unbound ANX5 was removed by washing prior to virus
transduction. We observed no effect of ANX5 on hGas6-medi-
ated transduction. These results show that Axl is the receptor
for hGas6 on HMVEC.
Transduction of 293T cells was not enhanced by hGas6,
hProtein S, or FCS (Figure 5D and data not shown). Consistent
with the above studies showing the role for Axl, 293T cells do
not express Axl (Figure 5E). To further demonstrate whether
any of the TAM receptors can mediate hGas6- or hProtein
S-mediated enhancement of viral transduction, we ectopically
expressed each of the TAM receptors on 293T cells (Figure 5E)
and tested whether expression could render 293T cells suscep-
tible to hGas6- or hProtein S-mediated viral transduction.
Although Mer is originally expressed on 293T cells, we overex-
pressed Mer to investigate its effects on enhancement of viral
transduction. Overexpression of Mer did not render the cells
susceptible to hGas6- or hProtein S-mediated enhancement,
but ectopic expression of Axl and TYRO3 rendered 293T cells
susceptible to hGas6-mediated viral transduction (Figure 5D).
Axl was more efficient in mediating enhancement. These results
are consistent with the known relative affinities of TAM receptors
for hGas6: the higher affinity of Axl, moderate affinity of TYRO3,
and low affinity of Mer for hGas6 (Stitt et al., 1995). hProtein S
can enhance transduction of Axl- and TYRO3-293T cells to a
lesser extent. These results demonstrated that Axl is the primary
receptor for hGas6-mediated viral transduction of HMVEC, but
TYRO3 can also serve as a receptor.
PtdSer as the Receptor for hGas6 on the Viral Envelope
Because Axl is the receptor on HMVEC for hGas6-mediated viral
transduction, the other ligand-binding site of Gas6, the Gla
domain, is likely to bind to virus. The ligand for the Gla domain
is PtdSer, and several viruses, including vaccinia virus and HIV,
expose PtdSer on their virion envelopes. Thus, PtdSer is most
likely the receptor for Gas6 on the viral envelope. We first inves-
tigated whether PtdSer is exposed on the lentiviral vectors by
using ANX5 as a probe. The 2.2 1L1L pseudotype was incubated
with ANX5, then the virus was purified by ultracentrifugation. The
purified virus was analyzed to determine whether ANX5 is copre-
cipitated with virus. Because the binding between PtdSer and
ANX5 is Ca2+ dependent, we performed binding in the presence
of Ca2+ or EGTA. Our results demonstrated that ANX5 bound to
virus in a Ca2+-dependent manner, indicating that PtdSer is
exposed on the envelope of lentiviral vectors (Figure 6A). To
confirm that hGas6 binds to virus through PtdSer, we investi-
gated whether ANX5 blocks binding of hGas6 to virus. Virus
was preincubatedwith hGas6 and purified by ultracentrifugation.
hGas6 was coprecipitated with virus, and the coprecipitation
was inhibited by EGTA (Figure 6B). As a control, hGas6(g),
which does not bind PtdSer, did not bind virus. PreincubationCellof virus with ANX5 inhibited binding of hGas6 to virus. The infec-
tivity of the virus incubated with hGas6 was 14-fold higher than
the virus without hGas6 or the virus incubated with hGas6 in
the presence of EGTA (Figure S3). These results demonstrated
that hGas6 binds to PtdSer on the viral envelope and that the
binding is dependent on both Ca2+ and g-carboxylation of the
hGas6 Gla domain.
We next demonstrated that blocking envelope PtdSer by
ANX5 can block hGas6-mediated enhancement of viral trans-
duction. We incubated the 2.2 1L1L pseudotype with ANX5
before transduction, then transduced HMVEC preincubated
with hGas6. Preincubation of the virus with ANX5 inhibited
hGas6-mediated enhancement of viral transduction, while trans-
duction of HMVEC (without preincubation with hGas6) with the
2.2 pseudotype conjugated with aHLA Ab was not affected by
ANX5 (Figure 6C). These results confirmed that PtdSer on the
viral envelope is necessary for hGas6-mediated enhancement
of transduction.
hGas6 Enhances Infection of Replication-Competent
Vaccinia Virus
Our studies using pseudotyped vectors revealed that the viruses
utilize a pathway that is normally used by phagocytes for recog-
nition of apoptotic cells. In that setting, PtdSer exposure of
apoptotic cells is recognized by TAM receptors on phagocytes
via bridging by Gas6/protein S. Since Gas6 is ubiquitous, we
speculate that this pathway for viral infection can be used when-
ever a virion contains PtdSer and TAM receptors are present on
target cells. Vaccinia virus was shown to use its envelope PtdSer
to enter into cells, a process referred to as ‘‘apoptotic mimicry of
viral entry’’ (Laliberte and Moss, 2009; Mercer and Helenius,
2008; Mercer et al., 2010). The cellular receptor for vaccinia virus
envelope PtdSer has not been identified, so we investigated
whether Gas6 is involved in PtdSer recognition and enhance-
ment of replication of vaccinia virus.
Vaccinia virus has two different forms, IMV and extracellular
enveloped virus (EEV) (Smith et al., 2002). The origin of envelope
lipids and the types of envelope proteins differ between IMV and
EEV. IMV is produced inside the cells, acquires its envelope
inside the cells from an unknown origin, and is released after lysis
of cells. EEV is comprised of IMV wrapped by an additional
membrane derived from the trans-Golgi network or early endo-
somes and buds out from the surface of cells.
Because the entry mechanisms and envelope structures of
IMV and EEV are distinct, we investigated the effect of hGas6
on both IMV and EEV infection. The replication-competent
vaccinia virus (WR strain) contains human CD4 as its reporter
gene under the control of a synthetic vaccinia strong early/late
promoter, which enables detection of infected cells by staining
with an anti-CD4 antibody. After infection, the cells were cultured
in the presence of cidofovir, which inhibits second-cycle replica-
tion of the virus (De Clercq et al., 1987), in order to analyze the
effect of hGas6 on a single infection cycle (Li et al., 2010).
hGas6 enhanced infection with IMV by only 1.1- to 1.3-fold,
regardless of moi (Figure 7A). However, hGas6 enhanced infec-
tion by EEV preparations 6.7-fold. These results demonstrated
that hGas6 can facilitate entry of replication-competent vaccinia
virus, predominantly by supporting replication of the EEV form.
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Figure 6. hGas6 Binds to Envelope PtdSer
(A) The 2.2 1L1L pseudotype (200 ng p24/ml) was
incubated with biotinylated ANX5 (25 mg/ml) in
PBS (+) or PBS (EGTA), followed by purification of
virus by ultracentrifugation. The same amount of
virus (4 ng p24/lane) was subjected to SDS-PAGE
and western blotting. ANX5 was detected using
HRP-conjugated streptavidin.
(B) The 2.2 1L1L pseudotype (200 ng p24/ml) was
incubated with PBS (+), PBS (+) containing ANX5
(25 mg/ml), or PBS (EGTA). The virus was then
incubated with hGas 6 or hGas6(g) (100 ng/ml) in
the conditions used for previous incubations. The
virus was purified by ultracentrifugation, and the
same amount of virus (1.6 ng p24/lane) was sub-
jected to SDS-PAGE and western blotting. hGas6
was detected using biotinylated anti-hGas6 anti-
body and HRP-conjugated streptavidin. (A and B)
The amounts of virus in each lane were confirmed
by immunoblotting of p24.
(C) HMVECs were incubated with PBS (+) or
PBS (+) containing hGas6 (100 ng/ml). The 2.2
pseudotype conjugated with aHLA Ab (2 mg/ml)
and 2.2 1L1L pseudotype (100 ng p24/ml) was
incubated with PBS (+) or PBS (+) containing
ANX5, and used for transduction of HMVEC with
or without pretreatment with hGas6. The error
bars represent standard deviations of triplicated
experiments. (See also Figure S3.)
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bating virus with ANX5 (Figure 7B). hGas6 did not enhance
EEV preparation’s infection of 293T cells but did enhance infec-
tion of Axl-293T cells (Figure 7C). hGas6 did not enhance IMV
infection of Axl-293T cells (Figure S4B).
EEV preparations may contain contaminating IMV and disrup-
ted EEV; thus, we cannot exclude the possibility that the pres-
ence of IMV and/or disrupted EEV in EEV preparation might
influence the results. Nevertheless, our results demonstrate
that EEV preparations obtained by standard methods are signif-
icantly enhanced by hGas6. These results demonstrate that
vaccinia virus can utilize the same apoptotic mimicry entry
pathway as lentiviral vectors.
DISCUSSION
We identified a Gas6-mediated entry mechanism which also
revealed the molecular mechanism by which envelope PtdSer
facilitates viral replication. This mechanism acts to provide an
alternative pathway for viral entry that is not limited by
specific interaction between viral envelope proteins and cell
receptors. This entry pathway seems to play a major role in viral
binding when native binding between virus and cells is weak.
Thus, Gas6 and protein S will broaden the tropisms of viruses.
Indeed, ectopic expression of Axl and TYRO3 was previously
shown to render unsusceptible cells susceptible to infection294 Cell Host & Microbe 9, 286–298, April 21, 2011 ª2011 Elsevier Inc.with Ebola virus by an unknown mecha-
nism (Shimojima et al., 2006). Axl- and
TYRO3-mediated infection of Ebola virus
might also involve bProtein S in FCS used
in cell cultures.Our data showed that lentiviral vectors pseudotyped with
various envelope proteins can be enhanced by hGas6 to differing
extents. The differences might be explained by varying affinities
and/or avidities of interaction between virus and target cells.
Binding by hGas6 can result in drastic increases in infectivity
when virus does not bind target cells efficiently (Figure 4D and
Figure S2B). Conversely, if viral binding is very efficient due to
high affinity and/or avidity interaction between virus envelope
proteins and target cells, the contribution of hGas6 to virus
binding is negligible. However, we cannot rule out the possibility
that these differences may be due to differing amounts of
exposed PtdSer dependent upon the pseudotyped envelope
protein.
Among the viruses known to use envelope PtdSer for its
replication, vaccinia virus is the only one clearly shown to use
PtdSer for its binding to target cells. This led us to test the
effects of hGas6 on vaccinia virus replication. The role of
PtdSer in vaccinia virus entry was shown by blocking replica-
tion of vaccinia virus using ANX5 and reconstituting the
membrane of detergent-extracted virions by PtdSer (Laliberte
and Moss, 2009; Mercer and Helenius, 2008; Mercer et al.,
2010). These investigations designated PtdSer-mediated virus
entry as apoptotic mimicry because exposed PtdSer was
known to be a surface marker of apoptotic cells. However,
these studies did not show whether the same PtdSer recogni-
tion mechanism is used for both phagocytosis of apoptotic
Figure 7. hGas6 Enhances Infection of the EEV Preparation of Vaccinia Virus
(A) HMVECs were incubated with PBS (+) or PBS (+) containing hGas6 (100 ng/ml). The IMV form was used for infection at mois of 0.1, 0.5, and 2.5. The EEV
preparation was used for infection at undetermined mois.
(B) HMVECs were incubated for 1 hr with PBS (+) or PBS (+) containing either normal goat IgG or goat anti-human Axl antibody (25 mg/ml) as a blocking reagent
and then incubated with hGas6 (100 ng/ml) in the presence of one blocking reagent for 4 hr. The EEV preparation (undiluted) was incubated for 1 hr with the same
volume of PBS (+) or PBS (+) containing ANX5 (25 mg/ml) and applied to HMVEC pretreated with hGas6 and blocking reagent.
(C) 293T and Axl-293T cells were incubated with AIM-V or AIM-V containing hGas6 (100 ng/ml), followed by infection with the EEV preparation (100-fold diluted
supernatant). (A–C) EEV preparations were pretreated with anti-A27L antibody to neutralize possible contamination of IMV (Figure S4) (Ichihashi, 1996). (A–C) The
error bars and values after ± represent standard deviations of triplicated experiments.
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entry can be mediated by the same molecular mechanism
used for recognition of dead cells. The differing degrees of
enhancement observed between the IMV and EEV preparations
of vaccinia virus could be due to several possibilities. (1) IMV
and EEV preparations have different envelope proteins on their
surfaces, resulting in different affinities of the virus for target
cells. (2) IMV and EEV obtain their envelopes from different
cytoplasmic organelles, potentially varying the amount of
exposed PtdSer. (3) EEV preparations are much less infectious
for HMVEC than IMV. Thus, as seen with lentiviral vector pseu-Celldotypes, the degree of enhancement is greater when native
infectivity is lower. One previous study demonstrated the role
of PtdSer in vaccinia virus entry using the IMV form (Mercer
and Helenius, 2008). We observed much less of an effect of
hGas6 on IMV, potentially due to different cell types used. (4)
The EEV outer membrane is fragile, so rupture of its outer
membrane may expose its luminal side, which contains abun-
dant PtdSer. Although the fragility of the outer envelope of
EEV makes analysis difficult, detailed biochemical analysis of
both the IMV and EEV envelope will be necessary to address
these possibilities.Host & Microbe 9, 286–298, April 21, 2011 ª2011 Elsevier Inc. 295
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includes proteins involved in the coagulation system (McCann
and Ames, 2009). The proteins of this family undergo g-carbox-
ylation, a posttranslational modification of glutamic acid resi-
dues, by VKD g-glutamylcarboxylase. We found that the Gla
domain of hGas6 binds to virus. Interestingly, the Gla domain
of factor X was also shown to bind adenovirus (Munch et al.,
2007). Although only a few proteins (less than 15) are known to
belong to the VKD protein family, four (protein C and factor VII,
IX, and X) were shown to mediate binding of nonenvelope virus
(adenovirus) (Parker et al., 2006), and two (Gas6 and protein S)
mediate binding of envelope virus. These results suggest
a common evolutional convergence where replication of diverse
viruses is enhanced by VKD proteins.
Gas6 shares 43% amino acid sequence homology with
Protein S, but there are differences in their expression and func-
tions (Fernandez-Fernandez et al., 2008; Hafizi and Dahlback,
2006). Protein S is mainly produced in the liver, but expression
of Gas6 is much lower in the liver than the heart, kidney, and
lung. hProtein S has an anticoagulant effect, but hGas6 does
not. Functions of protein S and Gas6 are also species depen-
dent. For example, while human and bovine protein S share
82% amino acid sequence identity, only the bovine variant is
shown to activate human TYRO3 (Evenas et al., 2000).
PtdSer is known to be exposed not only on vaccinia virus
envelope, but also on Pichinde virus (a model of Lassa fever
virus) and HIV (Callahan et al., 2003; Soares et al., 2008).
Although these studies did not indicate which step of viral repli-
cation is supported by PtdSer, both studies clearly demon-
strated that exposed PtdSer contributes to viral replication.
PtdSer of the plasma membrane is usually present in the inner
leaflet, while PtdSer of the membrane of cytoplasmic organelles
is present on both leaflets (Boon and Smith, 2002). Asymmetrical
distribution of PtdSer in the plasma membrane is maintained by
lipid transporters, flippases. When apoptosis or necrosis occurs,
flippases are inactivated and scramblase, which can transport
PtdSer in both directions, is activated, resulting in exposure
of PtdSer. There are three possible mechanisms that can expose
PtdSer on the viral envelope: (1) viral infection induces apoptosis
of infected cells and budding captures the exposed PtdSer
(Soares et al., 2008); (2) virions do not contain flippases, so it
cannot maintain asymmetrical distribution of PtdSer (Denard
et al., 2009); and (3) virus obtains envelope from cytoplasmic
organelles (Chertova et al., 2006). TAM receptors belong to the
receptor tyrosine kinase family that contains protein tyrosine
kinase activity within the cytoplasmic domain (Lemke and
Rothlin, 2008). Signaling via TAM receptors is reported to acti-
vate various signaling molecules, including PI3K, STAT3, and
Src. This signaling may facilitate endocytic and phagocytic
activity of cells, potentially affecting entry of virus. We tested
the activity of a tyrosine kinase inhibitor (SKI-606) on hGas6-
mediated transduction and observed a 2-fold reduction (data
not shown); however, because SKI-606 is a broad tyrosine
kinase inhibitor, we are unsure as to the significance of this
observation. TAM receptors are expressed on many cell types,
including hematopoietic cells, bone-marrow stromal cells, and
retinal pigment epithelial cells. Murine macrophages and
dendritic cells have been shown to express Axl and TYRO3
in vivo (Seitz et al., 2007). Since envelope PtdSer has been296 Cell Host & Microbe 9, 286–298, April 21, 2011 ª2011 Elsevier Inshown to enhance HIV replication in human macrophages
(Callahan et al., 2003), we prepared human macrophages by
in vitro differentiation of monocytes using GM-CSF (Lee et al.,
1999) to study the effects of hGas6 on HIV replication. Unfortu-
nately, we could not detect the expression of Axl and TYRO3
on the macrophages. However, monocyte-derived macro-
phages do not necessarily represent all types of macrophages
in vivo (Krutzik et al., 2005). It was shown that usage of IFN-a
for human dendritic cell differentiation from monocytes induces
expression of Axl while other differentiation conditions do not
(Scutera et al., 2009). Thus, different conditions for macrophage
differentiation could induce expression of Axl.
The serum concentration of hGas6 (200 pM) is higher than the
concentration required for viral transduction enhancement
(13 pM) (Hafizi and Dahlback, 2006). However, all hGas6 in
normal human serum has been shown to be bound with sAxl,
so it would not be able to mediate bridging of virus to cells
(Ekman et al., 2010b). Viral transduction enhancement by
hGas6 is expected to be suppressed in normal human serum.
We investigated whether human serum can enhance viral trans-
duction using two different lots of human sera, and we observed
only very weak enhancing activity (data not shown). Increased
plasma concentrations of Gas6 have been found in many
disease states, including malignancy and inflammation (Ekman
et al., 2010a). Importantly, Axl expression on endothelial cells
and vascular muscle is upregulated after vessel injury and
inflammation (Korshunov et al., 2006; Sharif et al., 2006). It is
well known that the virus can efficiently enter into the body via
the skin and mucosa when injury and/or inflammation occur
(Norkin, 2010). We theorize that injury and inflammation will facil-
itate virus entry not only by breaks of the barrier function of the
skin and mucosa, but also by the upregulation of Axl and Gas6
expression to enhance virus binding. This pathway could be
particularly important for viral binding if the expression of native
virus receptors is low at portal sites for viruses.
These studies began with efforts to identify factors respon-
sible for nonspecific infectivity of redirected lentiviral vectors.
Those efforts focused on both eliminating original receptor-
binding regions of the viral protein and conjugating virus with
ligands that specifically bind target cells and tissues. Here, we
demonstrate that a lipid can mediate binding of virus, which
should be considered when eliminating original tropism of viral
vectors and/or conferring new tropism by modification of enve-
lope lipids.
Because PtdSer is likely to be a common molecule among
many types of envelope viruses, further investigation of the entry
pathway mediated by PtdSer may lead to preventive and thera-
peutic approaches for viral diseases.
EXPERIMENTAL PROCEDURES
Cells, Viruses, Plasmids, and Proteins
See the Supplemental Experimental Procedures.
HMVEC Infection with Lentiviral Vectors
HMVECs were seeded 2 days before transduction for all infection and trans-
duction experiments. See the Supplemental Experimental Procedures for
the detailed conditions for lentiviral transduction.
Coprecipitation of the serum factor with the 2.2 1L1L pseudotype was per-
formed by incubating 2.2 1L1L in PBS (+) with 10% FCS followed byc.
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Gas6 Mediates Viral Entry via Apoptotic Mimicryultracentrifugation using a sucrose cushion. The pellet was resuspended in
PBS (+) and quantitated by measuring p24 amounts; the same amount of
viruses (100 ng p24/ml) was used for transduction of HMVEC.
To confirm bProtein S is the bridging factor, 10%FCSwas incubated for 1 hr
with sAxl or sCD4 and used to incubate HMVEC for 4 hr.
Purification of the Serum Factor from FCS and Protein Identification
See the Supplemental Experimental Procedures.
Binding of the Virus to ANX5 and hGas6
To investigate exposure of PtdSer on the viral envelope, 1 ml of the 2.2 1L1L
pseudotype (200 ng p24/ml) was incubated with biotinylated ANX5
(2.5 mg/ml) in PBS (+) or PBS containing 2 mM EGTA and 0.3% BSA (PBS
[EGTA]), followed by purification of the virus by ultracentrifugation. The
amounts of purified virus were measured by quantitating p24 by ELISA. The
same amounts of virus (4 ng p24) incubated with ANX5 in PBS (+) or PBS
(EGTA) were subjected to SDS-PAGE, western blotting, and staining with
streptavidin conjugated with horseradish peroxidase (HRP). To investigate
binding of hGas6 to virus, 0.5 ml of the 2.2 1L1L pseudotype (200 ng
p24/ml) was incubated with hGas6 (250 ng/ml) in PBS (+) or PBS (EGTA).
Viruses were purified by ultracentrifugation. The amounts of purified viruses
were quantitated by p24 ELISA. An equal amount of virus was subjected to
SDS-PAGE, western blotting, and immunostaining, using biotinylated anti-
hGas6 antibody and HRP-conjugated streptavidin. The amounts of virus in
each lane were confirmed by immunoblotting, using mouse anti-p24 mono-
clonal antibody and HRP-conjugated goat anti-mouse IgG.
Binding of the 2.2 1L1L Pseudotype with HMVEC
HMVECs (13 105) were incubated for 4 hr with hGas6 (100 ng/ml), hGas6(g)
(100 ng/ml), or FCS (10%) in 200 ml of PBS (+) or PBS (EGTA). The cells were
then incubated for 2 hr with 250 ml of the 2.2 1L1L pseudotype (250 ml, 100 ng
p24/ml) labeled with EGFP in the same buffer used for the previous incubation.
Vaccinia Virus Infection
The IMV form and EEV preparations of vaccinia virus were generated by infect-
ing BHK-21 cells with vaccinia virus according to the standard protocol (Law
and Smith, 2004). Please see the Supplemental Experimental Procedures for
more information.
SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures, Supplemental Experimental
Procedures, and Supplemental References and can be found with this article
at doi:10.1016/j.chom.2011.03.012.
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